Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 407 of the 409 references it cites were found in a registry or an index; 56 of the 148 sources its claims cite were checked for support.

The blood–brain barrier: Structure, regulation and drug delivery

Open access
Wu, Di, Chen, Qi, Chen, Xiaojie, Han, Feng, Chen, Zhong, Wang, Yi · 2023 · Signal Transduction and Targeted Therapy

Abstract

Blood-brain barrier (BBB) is a natural protective membrane that prevents central nervous system (CNS) from toxins and pathogens in blood. However, the presence of BBB complicates the pharmacotherapy for CNS disorders as the most chemical drugs and biopharmaceuticals have been impeded to enter the brain.

Overview

CoChat Summary

TL;DR

This is a review of the blood–brain barrier (BBB) that explains its structure, physiology, and the main strategies used to cross or modulate it for brain-targeted drug delivery. It surveys organic, inorganic, and biomimetic delivery systems and argues that better BBB models, safer materials, and more precise targeting are needed for translation.

Key findings

  • The BBB is described as a semi-permeable barrier formed mainly by endothelial cells, astrocytes, pericytes, tight junctions, and adherens junctions; it protects the CNS but also excludes “more than 98% of small-molecule drugs and all macromolecular therapeutics” from brain access.
  • The review groups BBB-crossing approaches into passive transcytosis, intranasal administration, ligand conjugation, membrane coating, external stimuli-mediated BBB disruption, and other non-invasive strategies.
  • It reports several quantitative examples from the literature, including:
  • passive transcytosis routes are limited to “hydrophilic compounds” under 150 Da and highly hydrophobic compounds under 400–600 Da;
  • one liposomal system showed brain accumulation peaking at 3 h and 48 h after injection;
  • cRGD-modified mesoporous silica nanoparticles (MSNs) of 20, 40, and 80 nm had transport capabilities of 44.0%, 59.2%, and 38.6%, respectively, versus 32.8% for free drugs;
  • a PLGA micelle system extended a drug’s therapeutic window from 20 min to at least 4 h.
  • The review highlights that many engineered systems can improve delivery, but clinical translation remains limited by safety, reproducibility, and the need for better targeting and evaluation models.

Methods

  • This is a narrative review, not an original experimental study.
  • It synthesizes prior studies on BBB structure/physiology and on brain-targeted delivery platforms, including liposomes, polymers, gold nanomaterials, carbon materials, iron oxide nanoparticles, silica nanomaterials, and biomimetic systems.
  • The main analysis is qualitative: it organizes strategies by BBB transport route/mechanism and compares reported examples from the literature, including preclinical and some clinical-trial-oriented work.

Limitations

  • The authors explicitly state that “a timely and comprehensive review is lacking,” indicating the field is broad and rapidly evolving.
  • They also say that “there is still a long way to go from clinical popularization and translational application,” and list unresolved issues including better BBB models, region-specific delivery, safety, interactions among components, scalability, and reproducibility.
  • Evident from the text: this paper is a review of published examples rather than a primary study, so it does not present a single unified dataset or direct experimental validation of the strategies discussed.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41392-023-01481-w

Cites

407 of 407 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Strategies and materials for BBB regulation and brain-targeted drug delivery. a Schematic diagram of different mechanisms for BBB crossing. b Schematic diagram of BBB structure. c Engineered materials for brain-targeted drug delivery. d Various non-invasive strategies for BBB crossing
Fig. 1 Strategies and materials for BBB regulation and brain-targeted drug delivery. a Schematic diagram of different mechanisms for BBB crossing. b Schematic diagram of BBB structure. c Engineered materials for brain-targeted drug delivery. d Various non-invasive strategies for BBB crossingCC BY · PubMed Central
Fig. 2 Intranasal administration allows rapid brain targeting from nose to brain. a Schematic illustration of the routes from the nasal cavity to the brain. b Transmission electron microscopy and structure schematic images of LENK nanoparticles. c The change of concentration of LENK in the olfactory bulb and cerebrum after the administration of nanopeptide or as the peptide alone. b, c Reproduced with permission. Copyright 2017, Elsevier. d Dynamics of fluorescence in rat trigeminal nerve. e Fluorescence intensity in the trigeminal nerve. f CSF concentration of Alexa-dextran. g Dynamics of MPEGePCLeTat complex in brain tissue. Reproduced with permission. d–g Reproduced with permission. Copyright 2013, Elsevier
Fig. 2 Intranasal administration allows rapid brain targeting from nose to brain. a Schematic illustration of the routes from the nasal cavity to the brain. b Transmission electron microscopy and structure schematic images of LENK nanoparticles. c The change of concentration of LENK in the olfactory bulb and cerebrum after the administration of nanopeptide or as the peptide alone. b, c Reproduced with permission. Copyright 2017, Elsevier. d Dynamics of fluorescence in rat trigeminal nerve. e Fluorescence intensity in the trigeminal nerve. f CSF concentration of Alexa-dextran. g Dynamics of MPEGePCLeTat complex in brain tissue. Reproduced with permission. d–g Reproduced with permission. Copyright 2013, ElsevierCC BY · PubMed Central
Fig. 3 Ligands conjugation is an active targeting strategy using ligands that have high specificity toward the receptor on the endothelial cells of the brain. a Schematic illustration of receptor-mediated drug delivery using ligands conjugated nanoparticles to the brain. b The MRI images of the brain of glioma-bearing mouse. The photo and micrograph image of glioma which was removed from U87-MG glioma nude mice. c Real-time imaging of the U87-MG glioma nude mice. b, c Reproduced with permission. Copyright 2020, Ivyspring International Publisher. d Microscopic visualization of nanoconjugates after permeating the BBB. Scale bar: 20 μm. Reproduced with permission. Copyright 2022, American Chemical Society. e Biodistribution results of NIR-797-labeled NP-5N and NP-5N-FRα-FA in ICR mice. Reproduced with permission. Copyright 2019, American Chemical Society
Fig. 3 Ligands conjugation is an active targeting strategy using ligands that have high specificity toward the receptor on the endothelial cells of the brain. a Schematic illustration of receptor-mediated drug delivery using ligands conjugated nanoparticles to the brain. b The MRI images of the brain of glioma-bearing mouse. The photo and micrograph image of glioma which was removed from U87-MG glioma nude mice. c Real-time imaging of the U87-MG glioma nude mice. b, c Reproduced with permission. Copyright 2020, Ivyspring International Publisher. d Microscopic visualization of nanoconjugates after permeating the BBB. Scale bar: 20 μm. Reproduced with permission. Copyright 2022, American Chemical Society. e Biodistribution results of NIR-797-labeled NP-5N and NP-5N-FRα-FA in ICR mice. Reproduced with permission. Copyright 2019, American Chemical SocietyCC BY · PubMed Central
Fig. 4 Cell membranes donate drug delivery systems with the brain targeting abilities. a Schematic illustration of examples of cell membrane coating strategies. b The fluorescence images of orthotopic U87-Luc glioblastoma tumor. c In vivo pharmacokinetics. d Quantification in different organs and tumor of (doxorubicin) DOX accumulation. b–d Reproduced with permission. Copyright 2018, Wiley-VCH. e The analysis of PD-1 levels on different phenotypes of macrophages. f The analysis of the PD-1+ cell ratio in different types of macrophages. g The fluorescence images pictured in groups of PLGA/DiR and PD-1-MM@PLGA/DiR. h Immunohistochemistry staining images. Scale bar: left 1 mm; right 50 μm. e–h Reproduced with permission. Copyright 2022, American Chemical Society. i Schematic illustration of the process of NK@AIEdots to inhibit the growth of the brain tumor. Reproduced with permission. Copyright 2020, American Chemical Society
Fig. 4 Cell membranes donate drug delivery systems with the brain targeting abilities. a Schematic illustration of examples of cell membrane coating strategies. b The fluorescence images of orthotopic U87-Luc glioblastoma tumor. c In vivo pharmacokinetics. d Quantification in different organs and tumor of (doxorubicin) DOX accumulation. b–d Reproduced with permission. Copyright 2018, Wiley-VCH. e The analysis of PD-1 levels on different phenotypes of macrophages. f The analysis of the PD-1+ cell ratio in different types of macrophages. g The fluorescence images pictured in groups of PLGA/DiR and PD-1-MM@PLGA/DiR. h Immunohistochemistry staining images. Scale bar: left 1 mm; right 50 μm. e–h Reproduced with permission. Copyright 2022, American Chemical Society. i Schematic illustration of the process of NK@AIEdots to inhibit the growth of the brain tumor. Reproduced with permission. Copyright 2020, American Chemical SocietyCC BY · PubMed Central
Fig. 5 Other strategies can achieve the intention of brain-targeted drug delivery. a Schematic illustration of examples of other strategies. b Fluorescence images using in vivo imaging system of isolated brains. c Schematic illustration of the weight drop-induced TBI model. d Time points of physically invaded BBB was studied. e Schematic illustration of the isolation of primary neuronal cells from mouse embryos. b–e Reproduced with permission. Copyright 2020, American Association for the Advancement of Science. f Ex vivo fluorescence images of primary organs of glioma-bearing mice. g Confocal images and corresponding fluorescence intensity of 3D tumor microspheres. f, g Reproduced with permission. Copyright 2022, Nature Publishing Group. h Evaluation of general toxicity, kidney function and liver function over time. Reproduced with permission. Copyright 2022, American Association for the Advancement of Science
Fig. 5 Other strategies can achieve the intention of brain-targeted drug delivery. a Schematic illustration of examples of other strategies. b Fluorescence images using in vivo imaging system of isolated brains. c Schematic illustration of the weight drop-induced TBI model. d Time points of physically invaded BBB was studied. e Schematic illustration of the isolation of primary neuronal cells from mouse embryos. b–e Reproduced with permission. Copyright 2020, American Association for the Advancement of Science. f Ex vivo fluorescence images of primary organs of glioma-bearing mice. g Confocal images and corresponding fluorescence intensity of 3D tumor microspheres. f, g Reproduced with permission. Copyright 2022, Nature Publishing Group. h Evaluation of general toxicity, kidney function and liver function over time. Reproduced with permission. Copyright 2022, American Association for the Advancement of ScienceCC BY · PubMed Central
Fig. 6 Liposomal formulations and polymeric materials for brain-targeted drug delivery. a Schematic illustration of synthesis of Apt-LP-LuH-6 liposomes and the structure characterization. Reproduced with permission. Copyright 2021, Elsevier. b Small-molecule-loaded ultrasound-controlled liposomal nanocarrier. Reproduced with permission. Copyright 2020, Nature Publishing Group. c Schematic illustration of synthesis of micelles by nanoprecipitation. Reproduced with permission. Copyright 2019, American Association for the Advancement of Science. d Schematic illustration of nanoprecipitation of peptide-modified PLGA and GALC CLEAs for the generation of enzyme delivery system. Reproduced with permission. Copyright 2021, Nature Publishing Group
Fig. 6 Liposomal formulations and polymeric materials for brain-targeted drug delivery. a Schematic illustration of synthesis of Apt-LP-LuH-6 liposomes and the structure characterization. Reproduced with permission. Copyright 2021, Elsevier. b Small-molecule-loaded ultrasound-controlled liposomal nanocarrier. Reproduced with permission. Copyright 2020, Nature Publishing Group. c Schematic illustration of synthesis of micelles by nanoprecipitation. Reproduced with permission. Copyright 2019, American Association for the Advancement of Science. d Schematic illustration of nanoprecipitation of peptide-modified PLGA and GALC CLEAs for the generation of enzyme delivery system. Reproduced with permission. Copyright 2021, Nature Publishing GroupCC BY · PubMed Central
Fig. 7 Gold nanomaterials and carbon materials for brain-targeted drug delivery. a Simulated structures of Aβ17-36 with L- and b D-GSH-coated Au (111) surface obtained from molecular docking simulation. Reproduced with permission. Copyright 2020, Nature Publishing Group. c Schematic illustration of synthesis and d TEM images of mazindol-B6 peptide-PCB-S-curcumin-siRNA (MBPCS) and intermediate products. Reproduced with permission. Copyright 2019, Royal Society of Chemistry. e Structures and reactivity of the various nuclearities of Ru-CO clusters on GO, and f FTIR spectra of 1Ru-and 11Ru-CO. Reproduced with permission. Copyright 2018, Wiley-VCH. g Schematic illustration of synthesis of drug-loaded graphene quantum dots (GQD-D) and Cetuximab-labeled red blood cell membrane-coated GQD-D anchored inside the nanosponge (Ct-RBC@GQD-D/NS) and h their TEM images. Reproduced with permission. Copyright 2019, American Chemical Society
Fig. 7 Gold nanomaterials and carbon materials for brain-targeted drug delivery. a Simulated structures of Aβ17-36 with L- and b D-GSH-coated Au (111) surface obtained from molecular docking simulation. Reproduced with permission. Copyright 2020, Nature Publishing Group. c Schematic illustration of synthesis and d TEM images of mazindol-B6 peptide-PCB-S-curcumin-siRNA (MBPCS) and intermediate products. Reproduced with permission. Copyright 2019, Royal Society of Chemistry. e Structures and reactivity of the various nuclearities of Ru-CO clusters on GO, and f FTIR spectra of 1Ru-and 11Ru-CO. Reproduced with permission. Copyright 2018, Wiley-VCH. g Schematic illustration of synthesis of drug-loaded graphene quantum dots (GQD-D) and Cetuximab-labeled red blood cell membrane-coated GQD-D anchored inside the nanosponge (Ct-RBC@GQD-D/NS) and h their TEM images. Reproduced with permission. Copyright 2019, American Chemical SocietyCC BY · PubMed Central
Fig. 8 Iron oxide nanoparticles, silica nanomaterials, biomimetic nanomaterials and Cas9/RNA nanoparticles for brain-targeted drug delivery. a Schematic illustration of synthesis of Fe3O4 nanoparticles-PLGA-perfluorohexane (PFH) nanoparticles with CREKA peptides and b, c representative TEM images of Fe3O4-PLGA-PFH-CREKA and PLGA-PFH-CREKA nanoparticles, and d their elemental mapping results. Reproduced with permission. Copyright 2019, American Chemical Society. e Schematic illustration of synthesis of HA-MMSN-1F12 nanoparticles and f particle size and g TEM images of HA-MMSN and HA-MMSN-1F12 nanoparticles. Reproduced with permission. Copyright 2022, Ivyspring International Publisher. h Schematic illustration of synthesis of cell membrane-coated nanostructures and its targeted synergistic therapy of glioblastoma. Reproduced with permission. Copyright 2022, Nature Publishing Group. i Schematic illustration of synthesis of CRISPR-Cas9 nanocapsules and j their TEM images and k size distribution. Reproduced with permission. Copyright 2022, American Association for the Advancement of Science
Fig. 8 Iron oxide nanoparticles, silica nanomaterials, biomimetic nanomaterials and Cas9/RNA nanoparticles for brain-targeted drug delivery. a Schematic illustration of synthesis of Fe3O4 nanoparticles-PLGA-perfluorohexane (PFH) nanoparticles with CREKA peptides and b, c representative TEM images of Fe3O4-PLGA-PFH-CREKA and PLGA-PFH-CREKA nanoparticles, and d their elemental mapping results. Reproduced with permission. Copyright 2019, American Chemical Society. e Schematic illustration of synthesis of HA-MMSN-1F12 nanoparticles and f particle size and g TEM images of HA-MMSN and HA-MMSN-1F12 nanoparticles. Reproduced with permission. Copyright 2022, Ivyspring International Publisher. h Schematic illustration of synthesis of cell membrane-coated nanostructures and its targeted synergistic therapy of glioblastoma. Reproduced with permission. Copyright 2022, Nature Publishing Group. i Schematic illustration of synthesis of CRISPR-Cas9 nanocapsules and j their TEM images and k size distribution. Reproduced with permission. Copyright 2022, American Association for the Advancement of ScienceCC BY · PubMed Central

Verification

Claims the paper makes

49 Valid · 1 Not valid · 72 Not checked · 14 Own results and interpretations

74 more claims · 26 with their cited sources checked

Create a free account to see all 136 claims and to verify the 5 references still open.

See all claims — free account
  • It may state two separate claims as one. 49
  • The quote only partly states this claim. 3
  • Probably not a substantial claim. 7

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

4 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Self-check results appear here once an independent check has confirmed them.

Cited works that were retracted

Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.

1 of 1

Citations

Cites

1 retracted

Show all 409 references

Research works printed but not linked: 1

  1. Oshra, B., Malka, S., Menachem, M. & Rachela, P. In Proc. SPIE, Nanoscale Imaging, Sensing, and Actuation for Biomedical Applications XVI. 108911H (2019).

Cited by

See all 1,906

Metadata

Authors
Wu, D., Chen, Q., Chen, X., Han, F., Chen, Z., & Wang, Y.
Affiliations
  • Zhejiang Chinese Medical University (CN)
  • Nanjing Medical University (CN)
Corresponding author
  • Wu, Di
  • Chen, Zhong
  • Wang, Yi
Venue
Signal Transduction and Targeted Therapy
Published
2023-05-25
Volume
8
Issue
1
Pages
217-217
ISSN
2059-3635 (ISSN-L)
OpenAlex
W4378217890
Cited by
1,906
References
409
Citations by year
2026: 723 · 2025: 785 · 2024: 351 · 2023: 46
FWCI
49.60
Type
journal article
Language
en
Open access
Licence
Locations
  • Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Natural Science Foundation of Zhejiang Province (LD22H310003)
  • National Natural Science Foundation of China (82003666)
  • National Foundation of Zhejiang Province
Topics
  • Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Keywords
blood-brain barrier, brain drug delivery, intranasal drug delivery, ligand conjugation, nanomaterials
MeSH terms
Biological Products, Biological Transport, Blood-Brain Barrier, Brain, Pharmaceutical Preparations, Drug Delivery Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The blood–brain barrier: Structure, regulation and drug delivery. https://app.cochat.ai/papers/10.1038/s41392-023-01481-w
The paper
Wu, D., Chen, Q., Chen, X., Han, F., Chen, Z., & Wang, Y. (2023). The blood–brain barrier: Structure, regulation and drug delivery. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-023-01481-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.